TITLE

PROTEO/MAYOLY SPINDLER FORM DRUG DEVELOPMENT PARTNERSHIP

PUB. DATE
July 2009
SOURCE
Worldwide Biotech;Jul2009, Vol. 21 Issue 7, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the drug development partnership between Protea Biosciences Inc. and Laboratoires Mayoly Spindler. Under the partnership, Protea will have exclusive North American marketing rights for the recombinant Lipase biopharmaceutical developed by the latter which could improve fat absorption in patients suffering from pancreatic insufficiency.
ACCESSION #
42633242

 

Related Articles

  • Manufacturing, Marketing And Distribution Agreements Between Biotech And Pharmaceutical Companies: May 29-June 25, 2009.  // BioWorld Insight;6/29/2009, Vol. 17 Issue 26, p11 

    The article offers information on manufacturing, marketing and distribution contracts signed between biotechnology and pharmaceutical firms from May 29-June 25, 2009. Biotechnology company Biosciences Inc. signed an agreement with Laboratoires Mayloy Spindler giving Protea exclusive marketing...

  • Cholecystokinin-stimulated peak lipase concentration in duodenal drainage fluid: a new pancreatic function test Conwell, Darwin L.; Zuccaro, Gregory; Morrow, J. Brad; Van Lente, Frederick; Obuchowski, Nancy; Vargo, John J.; Dumot, John A.; Trolli, Patricia; Shay, Steven S. // American Journal of Gastroenterology;Jun2002, Vol. 97 Issue 6, p1392 

    OBJECTIVE:Hormonal stimulation with secretin or cholecystokinin (CCK) is the most sensitive means of assessing pancreatic function. Secretin is not available, and current CCK tests are cumbersome, requiring dual tube intubation and marker perfusion techniques. The aim of this study was to test...

  • MPR Collaborator Protea Biosciences Wins "Top 10 Innovations of 2011" Technology Award.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article announces that MPR Associates Inc. collaborator Protea Biosciences has been awarded the "Top 10 Innovations of 2011" award by a life sciences journal "The Scientist," for its LAESI DP-1000 direct ionization system.

  • New formulation.  // Formulary;Aug2012, Vol. 47 Issue 8, p280 

    The article reports on a 2012 decision which the U.S. Food and Drug Administration made to approve Pancrelipase delayed-release capsules for the treatment of exocrine pancreatic insufficiency after conducting research on the drug's safety and efficacy.

  • CONTRACT SERVICES.  // R&D Magazine;Jun2013 Supplement, p30 

    A directory of companies that provide contract research, consulting, educational, and testing services is presented, which includes Protea Biosciences, Sem-Com Co., Inc., and SkyScan.

  • Pancreatic insufficiency in adult celiac disease: do patients require long-term enzyme supplementation? Evans, Kate E.; Leeds, John S.; Morley, Stephen S.; Sanders, David; Morley, Stephen; Sanders, David S // Digestive Diseases & Sciences;Oct2010, Vol. 55 Issue 10, p2999 

    Background: Celiac disease is associated with exocrine pancreatic insufficiency. We previously reported that in 30% (20/66) of adult celiac patients with current or persistent diarrhea the underlying cause was exocrine pancreatic insufficiency. Of these 20 patients, 19 initially...

  • Acute pancreatitis presenting as a perinephric pseudocyst. Goel, Tanmaya; Natarajan, K.; Chawla, Arun; Sasidharan, K. // Internet Journal of Surgery;2009, Vol. 20 Issue 2, p1 

    Acute pancreatitis presenting as a pseudocyst is well known. The sites of the pseudocyst are usually within the confines of the lesser sac. Herein we report a case of acute pancreatitis presenting principally as a perinephric pseudocyst.A perinephric pseudocyst is rare and can lead to diagnostic...

  • Evaluation of a Rapid Urine Amylase Test Using Post-ERCP Hyperamylasemia as a Model. Hegewald, Montgomery J.; Isenberg, Gerard; Sterling, Richard K.; Cooper, Gregory S.; Chak, Amitabh; Sivak Jr., Michael V. // American Journal of Gastroenterology (Springer Nature);Sep2001, Vol. 96 Issue 9, p2640 

    OBJECTIVE: The initial diagnosis of acute pancreatitis is often based on clinical criteria together with elevations of serum amylase and lipase. A reliable bedside urine test could facilitate the early diagnosis of pancreatitis. We evaluated a rapid urine amylase test (Rapignost) by using...

  • EDETATE CALCIUM DISODIUM CHELATING AGENT INHIBITS IN VITRO SERUM LIPASE AND AMYLASE ACTIVITY IN ACUTE PANCREATITIS. DEAC, MIRCEA; BARDAC, GABRIELA; MIHĂILĂ, ROMEO-GABRIEL // Acta Medica Transilvanica;dec2013, Vol. 18 Issue 4, p253 

    The good results obtained with chelating agent in the treatment of acute pancreatitis associated with saturnin colic suggested the question if they are not due to the enzymatic inhibition made by Edetate, Calcium Disodium. We have studied in vitro the effect of Edetate Calcium Disodium, on the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics